Furthermore, organoids derived from patients have illustrated that the modulation of the macrophage-capping protein (MCP)-GPX4/HMGB1 pathway can instigate immunogenic ferroptosis, thereby presenting a novel strategy to bolster anti-tumor immune responses [55]. This evidence concerns the gene GPX4 and neoplasm.